News About: Pharm. Industry
Government, drugmakers poles apart on drug price reform
The government and domestic drug firms remain far apart in their positions over the latter’s plan to cut drug prices by an average of 17 percent starting next year, which has triggered vehement protests from the domes...
Competition getting stiff for DPP-4 inhibitors
Following Bristol-Myers Squibb’s Onglyza (saxagliptin), Boehringer Ingelheim finally won the approval of the Korea Food and Drug Administration for their diabetes drug Trajenta (linagliptin), a dipeptidyl peptidase 4 ...
Court rejects drug price cuts lodged by health ministry
A court granted Tuesday Dong-A’s and Chong Kun Dang’s request for a preliminary injunction to suspend the improper reduction of insurance drug prices filed by the Ministry of Health and Welfare.
The ministry filed ...
Korean firms shy of R&D
Korean drug firms are showing a negative attitude towards research and development (R&D) due to the government’s plan to cut drug prices by an average of 17 percent starting next year, according to Rep. Choi Young-hee...
Pharmaceutical companies stalling on plant construction plan
Reflecting increasing uncertainty in the domestic pharmaceutical industry due to the government’s plan to cut drug prices starting next year, big corporations, Dong-A and Daewoong, are delaying the construction or re-...
Pharmaceutical wholesalers still sweating over falling margin
A majority of drug wholesalers are still struggling to sustain the current wholesaler margin, an industry observer said.
The government’s plan to cut the prices of generic drugs starting next year has led many drug...
Drug pricing reform will hurt domestic sector
A report released by IMS Health Korea said Korea's pharmaceutical sector could lose up to 2.28 trillion won if the government’s measures to cut medicine prices are adopted as planned starting next year.
“We have re...
Patents set to expire soon on many brand-name drugs
Patents for many blockbuster brand-name drugs begin expiring at a rapid pace in 2011 and will continue for the next few years.
Facing increased competition from generics, drug companies are busy developing new pipe...
Controversy remains over ‘pay for delay’
A tactic used in some drug patent settlement cases is creating renewed controversy concerning so-called “pay for delay” agreed between GlaxoSmithKline and Dong-A, which was made public by the Fair Trade Commission Thu...
Government’s plan to cut drug prices should be delayed
The Ministry of Health and Welfare said on August 2 that retail drug prices are expected to fall about 17 percent on average beginning next year following a set of government-led reforms.
However, Yuhan Corp. Presi...
